Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype.

OBJECTIVE To investigate the ability of statins, the inhibitors of the hydroxymethylglutaryl-coenzyme A reductase enzyme, to affect endothelial cell activation induced by anti-beta2-glycoprotein I (anti-beta2GPI) antibodies in vitro. METHODS Human umbilical vein endothelial cell (HUVEC) activation was evaluated as U937 monocyte adhesion, E-selectin, and intercellular adhesion molecule I (ICAM-1) expression by cell enzyme-linked immunosorbent assay and as interleukin-6 (IL-6) messenger RNA (mRNA) expression by RNA protection assay. E-selectin-specific nuclear factor kappaB (NF-kappaB) DNA-binding activity was evaluated by the gel-shift assay. HUVECs were activated by polyclonal affinity-purified IgG, human monoclonal IgM anti-beta2GPI antibodies, human recombinant IL-1beta, tumor necrosis factor alpha, or lipopolysaccharide (LPS). RESULTS Fluvastatin reduced, in a concentration-dependent manner (1-10 microM), the adhesion of U937 to HUVECs and the expression of E-selectin and ICAM-1 induced by anti-beta2GPI antibodies as well as by cytokines or LPS. Another lipophilic statin, simvastatin, displayed similar effects but to a lesser extent than fluvastatin. The inhibition of E-selectin expression exerted by fluvastatin was related to the impairment of NF-kappaB binding to DNA. Moreover, the drug attenuated the expression of IL-6 mRNA in HUVEC exposed to anti-beta2GPI antibodies or cytokines. Incubation of HUVECs with mevalonate (100 microM), concomitantly with fluvastatin, greatly prevented the inhibitory effect of statin. CONCLUSION Endothelial activation mediated by anti-beta2GPI antibody can be inhibited by statins. Because of the suggested role of endothelial cell activation in the pathogenesis of antiphospholipid syndrome (APS), our data provide, for the first time, a rationale for using statins as an additional therapeutic tool in APS.

[1]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[2]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[3]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[4]  F. Nicoletti,et al.  Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. , 2000, Journal of autoimmunity.

[5]  S. Reddel,et al.  Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. , 2000, Journal of autoimmunity.

[6]  T. Koike,et al.  2-glycoprotein Ianti-2-glycoprotein I Interaction , 2000 .

[7]  P. Gros,et al.  StructureFunction Studies on 2-glycoprotein I , 2000 .

[8]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[9]  L. Carreras,et al.  Which are the best biological markers of the antiphospholipid syndrome? , 2000, Journal of autoimmunity.

[10]  A. Gharavi,et al.  Experimental thrombosis and antiphospholipid antibodies: new insights. , 2000, Journal of autoimmunity.

[11]  Y. Shoenfeld,et al.  Heat shock protein 60/65, beta 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. , 2000, Journal of autoimmunity.

[12]  R. Pardi,et al.  Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein1 , 2000, The Journal of Immunology.

[13]  J. Farmer.  Pleiotropic effects of statins , 2000, Current atherosclerosis reports.

[14]  I. Bruce,et al.  Premature atherosclerosis in systemic lupus erythematosus. , 2000, Rheumatic diseases clinics of North America.

[15]  A. M. Lefer,et al.  Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. , 1999, Circulation.

[16]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[17]  A. Ridley,et al.  Monocyte Adhesion and Spreading on Human Endothelial Cells Is Dependent on Rho-regulated Receptor Clustering , 1999, The Journal of cell biology.

[18]  I. Barshack,et al.  Immunolocalization of b2-Glycoprotein I (Apolipoprotein H) to Human Atherosclerotic Plaques Potential Implications for Lesion Progression , 1999 .

[19]  A. Manning,et al.  Multiple signals converging on NF-κB , 1999 .

[20]  F. Bernini,et al.  HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Essig,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. , 1998, Circulation research.

[22]  Y. Shoenfeld,et al.  Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. , 1998, Circulation.

[23]  M. Khamashta,et al.  Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. , 1998, Journal of immunology.

[24]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[25]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[26]  M. Khamashta,et al.  β2-Glycoprotein I as a ‘Cofactor’ for anti-phospholipid reactivity with endothelial cells , 1998, Lupus.

[27]  G. Hughes,et al.  The Role of the Tissue Factor Pathway in the Hypercoagulable State in Patients with the Antiphospholipid Syndrome , 1998, Thrombosis and Haemostasis.

[28]  R. Roubey.  Mechanisms of autoantibody-mediated thrombosis , 1998, Lupus.

[29]  M. Khamashta,et al.  Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Anti‐Beta 2 Glycoprotein I Antibodies , 1997, American journal of reproductive immunology.

[30]  D. Granger,et al.  Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[31]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[32]  M. Khamashta,et al.  Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. , 1997, Arthritis and rheumatism.

[33]  Z. Makita,et al.  Involvement of β2‐glycoprotein I and anticardiolipin antibodies in oxidatively modified low‐density lipoprotein uptake by macrophages , 1997, Clinical and experimental immunology.

[34]  E. Tremoli,et al.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[35]  A. Tincani,et al.  The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. , 1996, Journal of immunology.

[36]  R. Roubey.  Immunology of the antiphospholipid antibody syndrome. , 1996, Arthritis and rheumatism.

[37]  C. Ballantyne,et al.  Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia , 1996 .

[38]  A. Tincani,et al.  Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? , 1995, Lupus.

[39]  A. Tincani,et al.  Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. , 1995, Clinical and experimental rheumatology.

[40]  G. Hughes,et al.  beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. , 1994, Arthritis and rheumatism.

[41]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[42]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[43]  R. Terkeltaub,et al.  Role of the mevalonate pathway of isoprenoid synthesis in IL‐8 generation by activated monocytic cells , 1994, Journal of leukocyte biology.

[44]  G. Gabbiani,et al.  Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. , 1993, Atherosclerosis.

[45]  W. Kübler,et al.  Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. , 1991, Atherosclerosis.

[46]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[47]  S. Grundy.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.

[48]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[49]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[50]  P. Tak,et al.  NF-κB: a key role in inflammatory diseases , 2001 .

[51]  P. Casali,et al.  Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. , 2000, Arthritis and rheumatism.

[52]  G. Hughes,et al.  Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus. , 1999, QJM : monthly journal of the Association of Physicians.